Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Immunol. 2021 Mar 5;206(7):1631–1641. doi: 10.4049/jimmunol.2000951

Figure 2. Inhibition of β5i with PKS3053 has no apparent toxicity for immune cells.

Figure 2.

PBMCs (n=6) were cultured for 24h with media alone or with either PKS3053 or ONX0914 at 0.03, 0.1, 0.3, 1 and 10 μM as indicated. The viability of (A) monocytes (CD14+ cells), (B) pDCs (CD14−CD11c− CD123+ BDCA4+ cells), (C) B cells (CD14−CD20+ cells), (D) T cells (CD14−CD3+ cells) and (E) cDCs (CD14−CD123−CD11c+ cells) was evaluated by flow cytometry. All results are represented as mean ± SEM. Statistical significance was evaluated using a Mann-Whitney U-test and *p≤0.05; **p≤0.01; ***p≤0.001